DOCSLIB.ORG

Skin Medicines Formulary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Skin Medicines Formulary Medicines Formulary Skin Contents: 1. Emollient preparations – general advice 2 2. Eczema and dry skin 2 i) Emollients 2 ii) Corticosteroids 4 iii) Tacrolimus and pimecrolimus 6 iv) Treatment for specific types of eczema 6 3. Psoriasis 9 i) Mild or chronic plaque psoriasis 9 ii) Scalp psoriasis 10 iii) Widespread, small psoriatic plaques 10 iv) Flexural psoriasis 10 v) Severe psoriasis 10 Biological agents 12 4. Skin irritation – prevention (use of barrier creams) 13 5. Pruritus or urticaria 14 6. Acne and rosacea 14 7. Topical fungal infections 16 8. Scabies 17 9. Head and pubic lice 18 10. Warts 18 11. Melasma 19 For full information on treatment, side effects, cautions and contraindications, see electronic British National Formulary (www.bnf.org) or the relevant summary of product characteristics (www.medicines.org.uk). For information on preparing intravenous medicines for administration, see Medusa Injectable Medicines Guide for the NHS (see Clinical Guidance home page) Skin — Medicines Formulary, Version 8f Principal author: Gareth Malson Updated with approvals from Wirral Drug and Therapeutics Committee: Sept 2017 Page 1 of 19 1. Emollient preparations – general advice Suitable quantities of emollients to be prescribed for specific areas of the body (assuming the emollient is used twice daily for one week) are: area of the body creams / ointments lotions face 15–30g 100mL both hands 25–50g 200mL both arms or both legs 100–200g 200mL trunk 400g 500mL groins and genitalia 15–25g 100mL An average adult requires 25g to cover whole body once. NOTE: These quantities will need to be increased significantly for patients with severe exacerbations of skin disease when emollients will need to be applied 5–6 times a day. If a rash is weeping / exudative use a cream or lotion. These are non occlusive and will allow evaporation to occur. If a rash is dry and scaly, use an ointment. The occlusive base will help to retain moisture. 2. Eczema and dry skin The mainstay of treatment for eczema and dry skin is regular use of emollients. Mild-to- moderate eczema can be managed with emollients alone. In more severe case, short bursts of moderate-to-high potency topical corticosteroids are required. Emollients can reduce a patient’s topical corticosteroid requirement. Inflammation of the skin can lead to loss of its barrier function. Emollients are moisturisers that soothe, smooth and hydrate the skin, leaving a protective layer that traps moisture and prevents the penetration of irritants by forming a protective barrier. An emollient provides a surface film of lipids and restores some of the barrier function. The importance of regular emollient use, particularly after skin washing and instead of soap, should be emphasised to patients. Patients with dry, lichenified rashes should use emollients liberally, both directly onto the skin and when bathing. All possible causes of contact dermatitis should be excluded. For dry, scaly eczema, emollients are essential to help reduce the use of topical steroids. A systemic antipruritic may also be required. i) Emollients NOTE: Patient choice is paramount when selecting an emollient for regular use. Emollients are most effective if used regularly. Empowering patients to choose their own emollient is established good practice and helps to increase concordance. Skin — Medicines Formulary, Version 8f Principal author: Gareth Malson Updated with approvals from Wirral Drug and Therapeutics Committee: Sept 2017 Page 2 of 19 • For acute exacerbations — greasier emollients (ie, ointments) are more effective • For maintenance treatment (between exacerbations) — lighter emollients (ie, creams and lotions) are often more tolerable. Many patients will require more than one emollient to suit their lifestyles (eg, a lighter one for use during the day, and a greasier one for use at night). If the emollient products listed prove unsuitable for a particular patient, clinicians should choose a cost-effective alternative, this should be communicated to the GP if recommended form secondary care.. For more information on the differences between emollients, and for tips on emollient use, see Emollients — advice for use. Directions Apply as a thin coating three or four times a day (using a downward motion in the direction of hair growth to avoid precipitating folliculitis). Take care if emollients are used in the bath as the surface will become slippery. Use regularly, particularly after skin washing. NOTE: Aqueous cream is NOT an effective moisturiser and can irritate some patients’ skin. It should NEVER be used as a leave-on emollient. Greasier emollients First choice • Oily cream (hydrous ointment BP) • Emulsifying ointment • 50% liquid paraffin / 50% white soft paraffin — particularly useful for dermatology inpatients, patients with very dry, scaly skin, and for applying to the skin surrounding leg ulcers (this is prone to becoming very dry) Second choice • Hydromol® ointment Third choice • Epaderm® ointment • Diprobase® ointment Clinicians are advised to use small quantities of cream to allow patients to find an emollient that suits them, but then prescribe larger quantities for regular use. Emollient creams First choice • E45® cream — lowest cost, try first • Cetraben® cream • Diprobase® cream • Doublebase® gel Second choice • Epaderm® cream Skin — Medicines Formulary, Version 8f Principal author: Gareth Malson Updated with approvals from Wirral Drug and Therapeutics Committee: Sept 2017 Page 3 of 19 • Oilatum® cream • Oilatum Junior® cream Third choice • Hydromol® cream — considerably more expensive than other formulary choices Emollient lotions First choice • E45® lotion Second choice • QV® lotion Bath/shower products Patients with chronic skin conditions often require total emollient therapy (ie, a mixture of emollients including one to use as a soap substitute or bath oil). Care should be taken when using bath oils because they can make the bathtub slippery and some are unsuitable for application directly onto the skin. First choice • Emulsifying ointment Second choice — for showering • Oilatum gel® (as soap substitute) • Doublebase bath and shower emollient® (as soap substitute) Second choice — for use in the bath • Oilatum® (bath emollient) • QV® bath oil Other emollients The following preparations should ONLY be prescribed on the advice of a dermatology specialist: • Dermamist® spray • Emollin® spray • Aveeno® cream Urea-containing creams Urea applied topically can help to treat persistent itching. See section 5 (“Pruritis and itching”). ii) Corticosteroids If corticosteroid use is indicated ointments are preferable to creams as they have a deeper, more prolonged emollient effect and increase the penetration of steroid. It is worth trying different topical steroids within the same potency classification since there can be inter-patient variability. The potency should be kept to the lowest that is effective. Skin — Medicines Formulary, Version 8f Principal author: Gareth Malson Updated with approvals from Wirral Drug and Therapeutics Committee: Sept 2017 Page 4 of 19 Site (for adult patients) acute eruption reduce to face moderate mild trunk/limbs potent moderate scalp Very potent / potent potent hands / feet Very potent potent As a guide if no response is achieved after short-term use of two different preparations in the following quantities, refer to a dermatologist. Suitable quantities of corticosteroids for two weeks’ treatment are: • Trunk: 100g to 200g • Arms and legs: 100g to 200g • Whole body: 300g to 400g Central serous chorioretinopathy is a retinal disorder that has been linked to the use of corticosteroids – please refer to the MHRA drug safety update, August 2017 at: https://www.gov.uk/drug-safety-update/corticosteroids-rare-risk-of-central-serous- chorioretinopathy-with-local-as-well-as-systemic-administration Mild potency • Hydrocortisone 1% cream / ointment Moderately potent • Clobetasone butyrate (Eumovate®) 0.05% cream / ointment • Betamethasone valerate (Betnovate-RD®) 0.025% cream / ointment • Fludroxycortide (Haelan®) 0.0125% cream / tape (4microgram/cm2) • Fluocinolone acetonide (Synalar 1-in-4®) 0.00625% cream / ointment NOTE: Considerably more expensive than other preparations. Only use for patients who are intolerant of other corticosteroids Potent — do not use on children without specialist advice • Betamethasone valerate (Betnovate®) 0.1% cream / ointment / lotion / scalp application • Betamethasone diproprionate (Diprosone®) 0.05% cream / ointment • Fluocinonide (Metosyn®) 0.05% ointment • Fluocinolone acetonide (Synalar®) 0.025% cream / ointment / gel NOTE: Considerably more expensive than other preparations. Only use for patients who are intolerant of other corticosteroids • Betamethasone valerate (Betesil®) plasters — for initiation by dermatologists ONLY for chronic lichenified eczema For resistant eczema and hyperkeratotic patches (particularly on the hands and feet) Betamethasone 0.05% and salicylic acid 3% (Diprosalic®) ointment Very potent — do not use without specialist advice • Clobetasol propionate (Dermovate®) 0.05% cream / ointment / scalp application Directions Apply thinly once or twice daily (wash hand(s) after use). Patients should be advised that one fingertip unit (the amount of cream that is squeezed from a standard tube along an adult’s fingertip) is sufficient to cover an area of the body the size of two of the same Skin — Medicines Formulary, Version 8f Principal author: Gareth Malson Updated with approvals from Wirral Drug and Therapeutics Committee: Sept
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • St John's Institute of Dermatology
    St John’s Institute of Dermatology Topical steroids This leaflet explains more about topical steroids and how they are used to treat a variety of skin conditions. If you have any questions or concerns, please speak to a doctor or nurse caring for you. What are topical corticosteroids and how do they work? Topical corticosteroids are steroids that are applied onto the skin and are used to treat a variety of skin conditions. The type of steroid found in these medicines is similar to those produced naturally in the body and they work by reducing inflammation within the skin, making it less red and itchy. What are the different strengths of topical corticosteroids? Topical steroids come in a number of different strengths. It is therefore very important that you follow the advice of your doctor or specialist nurse and apply the correct strength of steroid to a given area of the body. The strengths of the most commonly prescribed topical steroids in the UK are listed in the table below. Table 1 - strengths of commonly prescribed topical steroids Strength Chemical name Common trade names Mild Hydrocortisone 0.5%, 1.0%, 2.5% Hydrocortisone Dioderm®, Efcortelan®, Mildison® Moderate Betamethasone valerate 0.025% Betnovate-RD® Clobetasone butyrate 0.05% Eumovate®, Clobavate® Fluocinolone acetonide 0.001% Synalar 1 in 4 dilution® Fluocortolone 0.25% Ultralanum Plain® Fludroxycortide 0.0125% Haelan® Tape Strong Betamethasone valerate 0.1% Betnovate® Diflucortolone valerate 0.1% Nerisone® Fluocinolone acetonide 0.025% Synalar® Fluticasone propionate 0.05% Cutivate® Hydrocortisone butyrate 0.1% Locoid® Mometasone furoate 0.1% Elocon® Very strong Clobetasol propionate 0.1% Dermovate®, Clarelux® Diflucortolone valerate 0.3% Nerisone Forte® 1 of 5 In adults, stronger steroids are generally used on the body and mild or moderate steroids are used on the face and skin folds (armpits, breast folds, groin and genitals).
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Topical Corticosteroids Available at Leeds Teaching Hospitals Information
    Medicines Management & Pharmacy Services (MMPS) Topical Corticosteroids Available at Leeds Teaching Hospitals Information Mild to Moderate Potency ( Potent and very potent on the following page) Mild Corticosteroids: Brand Name Active Ingredients Formulation Dioderm ® Hydrocortisone 0.1% Cream Hydrocortisone Hydrocortisone 0.5% Cream and Ointment Hydrocortisone Hydrocortisone 1% *suggested first line formulary choice* Cream and Ointment Hydrocortisone Hydrocortisone 2.5% Cream Mild Corticosteroids with Antimicrobials Brand Name Active Ingredients Formulation Canestan HC ® Hydrocortisone 1%, Clotrimazole 1% Cream Daktacort ® Hydrocortisone 1%, Miconazole nitrate 2% Cream and Ointment Fucidin H ® Hydrocortisone 1%, Fusidic acid 2% Cream Hydrocortisone 0.5%,Nystatin 100,000units/g, Benzalkonium Timodine ® chloride 0.2%, Dimeticone ‘350’ 10% Cream Moderate Corticosteroids Brand Name Active Ingredients Formulation Betnovate RD ® Betamethasone 0.025% *suggested first line formulary choice* Ointment Eumovate ® Clobetasone butyrate 0.05% Cream and Ointment Fludroxycortide Fludroxycortide 0.0125% Cream, Ointment, Tape Moderate Corticosteroids with Antimicrobials Brand Name Active Ingredients Formulation Trimovate ® Clobetasone butyrate 0.05%, Oxytetracycline 3%, Cream Nystatin 100,000 units/g Potent and Very Potent (mild and moderate potency on previous page) Potent Corticosteroids Brand Name Active Ingredients Formulation Betnovate ® Betamethasone valerate 0.1% *suggested first line formulary choice* Scalp application Betamethasone Betamethasone
    [Show full text]
  • United States Patent (10) Patent No.: US 9.447,027 B2 Milan Et Al
    US009447027B2 (12) United States Patent (10) Patent No.: US 9.447,027 B2 Milan et al. (45) Date of Patent: Sep. 20, 2016 (54) TREATING LONG QT SYNDROME 2004/O1972.71 A1* 10, 2004 Kunka et al. ................... 424/45 2006/0173058 A1* 8, 2006 Brown .................... CO7C 65/05 514,381 (75) Inventors: Es l, St. MS 2006/0173508 A1* 8, 2006 Stone ................. A61N 1,36085 aVId S. Peal, SomerV11 le. (US) 607/40 (73) Assignee: The General Hospital Corporation, FOREIGN PATENT DOCUMENTS Boston, MA (US) JP 11209328 A1 * 8, 1999 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 86 days. Nademanee, K. et al., Annals of the New York Academy of Sciences vol. 522, pp. 536-552, published 2006.* (21) Appl. No.: 13/822,264 Chouabe, C. et al., Molecular Pharmacology vol. 54 pp. 696-703, published 1998.* (22) PCT Filed: Oct. 20, 2011 Nishizawa, S., et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.e1-1167.e3, published Nov. 2009).* (86). PCT No.: PCT/US2011/057087 Nishizawa et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.el -1167.e3, published Nov. 2009).* S 371 (c)(1), Nishizawa et al (American Journal of Emergency Medicine vol. 27. (2), (4) Date: Jul. 22, 2013 pp. 1167.e1-1167.e3, published Nov. 2009).* Anderson et al., “Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism.” Circula (87) PCT Pub. No.: WO2012/054718 tion 113:365-373, 2006, 10 pages.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Topical Corticosteroids Used at Leeds Teaching Hospitals Information
    Medicines Management & Pharmacy Services (MMPS) Topical Corticosteroids used at Leeds Teaching Hospitals Information Mild and moderate potency (potent and very potent on following page) Mild Corticosteroids Brand Name Active Ingredients Formulation Dioderm ® Hydrocortisone 0.1% Cream Hydrocortisone Hydrocortisone 0.5% Cream and Ointment Hydrocortisone Hydrocortisone 1% Cream and Ointment Hydrocortisone Hydrocortisone 2.5% Cream Mild Corticosteroids with Antimicrobials Brand Name Active Ingredients Formulation Canestan HC ® Hydrocortisone 1%, Clotrimazole 1% Cream Daktacort ® Hydrocortisone 1%, Miconazole nitrate 2% Cream and Ointment Fucidin H ® Hydrocortisone 1%, Fusidic Acid 2% Cream Timodine ® Hydrocortisone 0.5%,Nystatin 100,000units/Chlorhexidine 1% Cream Other Mild Corticosteroid Combination Preparations Brand Name Active Ingredients Formulation Eurax-HC ® Hydrocortisone 0.25%, Crotamiton 10% Cream Moderate Corticosteroids Brand Name Active Ingredients Formulation Betnovate RD ® Betamethasone 0.025% Cream and Ointment Eumovate ® Clobetasone Butyrate 0.05% Cream and Ointment Cream, Ointment, Haelan ® Fludroxycortide 0.0125% Tape Moderate Corticosteroids with Antimicrobials Brand Name Active Ingredients Formulation Trimovate ® Clobetasone Butyrate 0.05%, Oxytetracycline 3% Cream Nystatin 100 000 units/g Other Moderate Corticosteroid Combination Preparations None stocked at LTHT References and Provenance Date Produced: 14/12/2011 Valid until: 14/12/2013 Review Date: Author: Nora Sadiq, pharmacist Quality Assurance Check by: Steve Ashmore,
    [Show full text]
  • Guide to Treatments Used for Atopic Dermatitis in Adults
    ■ THERAPY REVIEW Guide to treatments used for atopic dermatitis in adults STEVE CHAPLIN Atopic dermatitis, or eczema, usually begins in childhood but adults can also 20 be affected due to either persistence of symptoms or late-onset disease. This 15 article provides a guide to the topical and systemic treatments used for 10 atopic dermatitis in adults, including administration, adherence and primary % Prevalence care prescribing data. 5 0 30s 40s 50s 60s 70s 80s Age group (years) Figure 1. One-year prevalence of atopic dermatitis in adults according to age, Denmark (n=16,507)7 ccording to surveys of the prevalence of atopic dermatitis, A3–17 per cent of adults self-report having the condition,1-9 though estimates are lower when confirmed by a medical diag- nosis (1.6–10 per cent4,10-12). The reported prevalence over longer time periods, eg eight years10 or lifetime,1 ranges more widely, from about 3 per cent to 40 per cent. Most of those affected had atopic dermatitis during childhood or had a family history of the condition,1,2 though onset during adulthood is also described.6 In one study in which dermatologists graded atopic dermatitis severity, 71 per cent of cases were mild, 26 per cent were moderate and 4 per cent were severe.4 It has been assumed that children with atopic dermatitis ‘grow out’ of the condition but, by young adulthood, about 80 per cent have persistent symptoms.13 A large survey in Denmark (n=16,507) found that one-year prevalence of atopic dermatitis among adults declined with age but it was still common among people in their 80s (see Figure 1).7 Two large (n=833 and n=955) studies reported follow-up of at least 24–25 years in cohorts who had attended dermatology clinics during childhood.
    [Show full text]
  • Steroid Ladder
    Formulary (GMMMG) | 1‐ First choice | 2‐ Second choice STEROID LADDER DO NOT Very Potent USE ON • Eyelids • Face See Drug safety update Dermovate (clobetasol proprionate 0.05%) • Groin Corticosteroids: rare risk of • Armpits Dermovate scalp lotion (clobetasol proprionate 0.05%) central serous chorioretinopathy • Genitals Etrivex shampoo (clobetasol proprionate 500 micrograms/g) with local as well as systemic • Children • Psoriasis administration Potent Betnovate (betamethasone valerate 0.1% in a water miscible With salicylic acid base) Diprosalic DO NOT Betacap (betamethasone valerate 0.1% containing coconut oil (betamethasone diproprionate 0.05%, USE ON derivative) salicylic acid 3%) • Eyelids Locoid (hydrocortisone butyrate 0.1%) • Face Synalar (fluocinolone acetonide 0.025%) With vitamin D (for use in psoriasis only) • Groin Elocon (mometasone furoate 0.1%) Dovobet • Armpits (betamethasone diproprionate 0.05%, • Genitals • Children With antibacterial calcipotriol 50micrograms/g) without Fucibet (betamethasone valerate 0.1%, fusidic acid 2%) Enstilar expert Synalar C (fluocinolone acetonide 0.025%, clioquinol 3%) (betamethasone diproprionate 0.05%, opinion Synalar N (fluocinolone acetonide 0.025%, neomycin sulfate calcipotriol 50micrograms/g) 0.5%) Moderate Betnovate RD (betamethasone valerate 0.25%) With Urea Eumovate (clobetasone butyrate 0.05%) Alphaderm (hydrocortisone 1%, urea 10%) DO NOT USE ON 2 Fludroxycortide Tape (4 micrograms/cm ) With antifungal and antibacterial Modrasone (Alclometasone dipropionate 0.05%) Trimovate Eyelids
    [Show full text]
  • 13.4: Topical Corticosteroids
    Doncaster & Bassetlaw Medicines Formulary Section 13.4: Topical Corticosteroids Potency: Mild Hydrocortisone 1% cream & ointment Moderate Betamethasone 0.025% cream & ointment Clobetasone 0.05% cream & ointment Potent Betamethasone 0.1% cream, ointment & scalp application WITH SALICYLIC ACID Betamethasone 0.05% plus Salicylic Acid 3% ointment (Diprosalic) Betamethasone 0.05% plus Salicylic Acid 2% scalp Application (Diprosalic) Approved by Drug and Therapeutics Committee: March 2018 Review Date: March 2021 Prescribing Guidance: Topical corticosteroids are used for the treatment of inflammatory conditions of the skin. They are not curative and on stopping treatment a rebound exacerbation of the condition may occur. Choice of formulation Corticosteroids are categorised as mild, moderate, potent and very potent (see above); the least potent preparation which is effective should be used. Water miscible creams are suitable for moist or weeping lesions. Ointments are used for dry lichenified or scaly lesions where a more occlusive effect is required. Occlusion under polythene or a hydrocolloid dressing increases the absorption of the corticosteroid and thus the risk of side effects. Side effects can occur particularly with the potent/very potent preparations. These include thinning of the skin, irreversible striae atrophicae, contact and perioral dermatitis, and acne or worsening acne. To minimise side effects it is important to apply the topical steroid thinly to the affected area only no more than twice a day. KEY: [UL] Unlicensed Preparation; Drug – first line choice; Drug – hospital only; Drug – Amber (TLS), Drug – Red (TLS), see http://medicinesmanagement.doncasterpct.nhs.uk/ Contra-indications Use in untreated bacterial, fungal or viral skin lesions, acne rosacea, and perioral dermatitis.
    [Show full text]
  • Steroid Treatments for Eczema
    STEROID TREATMENTS FOR ECZEMA Millions of people suffer from “atopic” eczema. This is the most common type of eczema. It causes dry skin that‟s prone to flare-ups of a very itchy rash. When the eczema flares up, a steroid cream or ointment is the recommended treatment. However, many people worry about steroids because of possible side-effects. This issue of Treatment Notes is for anyone concerned about using steroids for atopic eczema – either on themselves or their child. It explains how, used correctly, these steroids are very effective and rarely cause problems. What‟s Inside . Atopic eczema . How do steroids fit in? . Pros and cons of steroids . Treating a flare-up . What if it doesn‟t clear up? Atopic eczema There are several types of eczema – also known as dermatitis. The most common type is called „atopic‟ eczema. „Atopic‟ means a problem caused by an allergy to certain common things, such as house dust, animal hair or some foods. The cause of atopic eczema isn‟t fully understood, but seems to involve the immune system. People who have it often also have other atopic problems such as hay fever or asthma. Eczema typically flares up in skin creases, such as at the elbows and knees and around the neck. It can affect large areas of skin, and make it crack or bleed. Eczema, particularly when severe, can also make the skin prone to infection. Even though most people have quite mild eczema, the itching, pain and loss of sleep can be very upsetting and disrupt school, work or other activities.
    [Show full text]